Global Traveler's Diarrhea Therapeutics Market Expected to Witness a Sustainable Growth over 2023

New report published by Market Research Report Store (MRRS) which offers insights on the global Traveler's Diarrhea Therapeutics market.

Traveler's diarrhea (TD) is a stomach and intestinal infection. TD is defined as the passage of unformed stool (one or more by some definitions, three or more by others) while traveling. It may be accompanied by abdominal cramps, nausea, fever, and bloating. Occasionally bloody diarrhea may occur. Most travelers recover within four days with little or no treatment. About 10% of people may have symptoms for a week.

Click to view the full report TOC, figure and tables:
https://www.marketresearchreportstore.com/reports/241695/global-traveler-s-diarrhea-therapeutics-market

Global Traveler's Diarrhea Therapeutics Market: Forecast by Type / Application / Region

Traveler’s diarrhea is the leading cause of illness among international travelers to developing countries. Enterotoxigenic Escherichia coli (ETEC) bacteria are the primary cause of this disease. Among the estimated 65 million travelers from industrialized countries to high-risk areas in the developing world, as many as 50% may experience at least one TD episode during their journey. ETEC is usually responsible for 22-60% of all TD cases in both civilian and military groups or about 7-18 million cases per year. ETEC is also a major cause of diarrheal disease in children living in countries endemic for ETEC, leading to over 400 million diarrheal episodes and approximately 300,000 deaths each year.

The classification of Traveler’s Diarrhea Therapeutics includes Immunization, Non-antibiotic Agents, Antibiotics, Anti-Motility Agents, Other. And the proportion of Non-antibiotic Agents in 2017 is about 36%, and And the proportion of Anti-Motility Agents in 2017 is about 20%.

According to this study, over the next five years the Traveler's Diarrhea Therapeutics market will register a 7.1% CAGR in terms of revenue, the global market size will reach US$ 890 million by 2024, from US$ 630 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Traveler's Diarrhea Therapeutics business, shared in Chapter 3.

Global Traveler's Diarrhea Therapeutics Market: Key Players
Salix Pharmaceuticals
P&G
Johnson & Johnson
Otsuka Pharma
Valneva
Shanghai United Cell
PaxVax
Livzon
Immuron

Ask for Discount on Research Report and Request Sample Copy of Report@
https://www.marketresearchreportstore.com/reports/241695/global-traveler-s-diarrhea-therapeutics-market

Related Information:
United States Traveler's Diarrhea Therapeutics Market Research Report 2018
Europe Traveler's Diarrhea Therapeutics Market Research Report 2018
North America Traveler's Diarrhea Therapeutics Market Research Report 2018
Asia-Pacific Traveler's Diarrhea Therapeutics Market Research Report 2018
China Traveler's Diarrhea Therapeutics Market Research Report 2018
EMEA Traveler's Diarrhea Therapeutics Market Research Report 2018
Global Traveler's Diarrhea Therapeutics Market Research Report 2018

About Us:
Market Research Report Store (MRRS) is a professional organization related to market research reports in all directions .To provide customers with a variety of market research reports, MRRS cooperates with a large of famous market report publishers all over the world. Owing to our good service and the professional market reports in the wide range, MRRS enjoys a good reputation in the market. In pace with the development of MRRS, more and more customers and market report publishers choose to cooperate with us. As a specialized platform, MRRS upholds the supremacy of customers and aims to provide customers with better service and richer select.

Contact US :
Sales Director (Market Research Report Store)
E-mail: info@marketresearchreportstore.com
Tel: +86-15521064060 00852-58197708(HK)
Add: 17890 Castleton Street Suite 218 City of Industry CA 91748 United States
Website: https://www.marketresearchreportstore.com

This release was published on openPR.